ACAD
Price
$17.19
Change
-$0.37 (-2.11%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
2.93B
63 days until earnings call
DNLI
Price
$14.96
Change
-$1.73 (-10.37%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
2.42B
63 days until earnings call
Ad is loading...

ACAD vs DNLI

Header iconACAD vs DNLI Comparison
Open Charts ACAD vs DNLIBanner chart's image
ACADIA Pharmaceuticals
Price$17.19
Change-$0.37 (-2.11%)
Volume$69.49K
Capitalization2.93B
Denali Therapeutics
Price$14.96
Change-$1.73 (-10.37%)
Volume$31.75K
Capitalization2.42B
ACAD vs DNLI Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. DNLI commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (ACAD: $17.56 vs. DNLI: $16.69)
Brand notoriety: ACAD and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 52% vs. DNLI: 149%
Market capitalization -- ACAD: $2.93B vs. DNLI: $2.42B
ACAD [@Biotechnology] is valued at $2.93B. DNLI’s [@Biotechnology] market capitalization is $2.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 4 bearish.
  • DNLI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than DNLI.

Price Growth

ACAD (@Biotechnology) experienced а -10.41% price change this week, while DNLI (@Biotechnology) price change was +0.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

ACAD is expected to report earnings on May 13, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.93B) has a higher market cap than DNLI($2.42B). ACAD YTD gains are higher at: -4.305 vs. DNLI (-18.106). ACAD has higher annual earnings (EBITDA): 125M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. ACAD (565M). ACAD has less debt than DNLI: ACAD (49.4M) vs DNLI (52.5M). ACAD has higher revenues than DNLI: ACAD (929M) vs DNLI (0).
ACADDNLIACAD / DNLI
Capitalization2.93B2.42B121%
EBITDA125M-496.05M-25%
Gain YTD-4.305-18.10624%
P/E Ratio12.64N/A-
Revenue929M0-
Total Cash565M837M68%
Total Debt49.4M52.5M94%
FUNDAMENTALS RATINGS
ACAD vs DNLI: Fundamental Ratings
ACAD
DNLI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3591
PRICE GROWTH RATING
1..100
6090
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as DNLI (94). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

ACAD's SMR Rating (35) in the Biotechnology industry is somewhat better than the same rating for DNLI (91). This means that ACAD’s stock grew somewhat faster than DNLI’s over the last 12 months.

ACAD's Price Growth Rating (60) in the Biotechnology industry is in the same range as DNLI (90). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ACAD (100). This means that DNLI’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADDNLI
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
73%
Momentum
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
76%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
83%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFUVX32.450.23
+0.71%
DFA US Large Cap Value III
NIQCX13.850.09
+0.65%
Neuberger Berman International Eq C
DMCYX29.690.19
+0.64%
BNY Mellon Opportunistic Midcap Value Y
NDGCX21.430.13
+0.61%
Neuberger Berman Dividend Growth C
CEUAX56.700.09
+0.16%
American Funds Europacific Growth 529A

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-0.28%
RGNX - ACAD
44%
Loosely correlated
-1.71%
MGTX - ACAD
40%
Loosely correlated
-1.24%
STTK - ACAD
39%
Loosely correlated
-7.52%
TECH - ACAD
39%
Loosely correlated
+1.55%
DNLI - ACAD
39%
Loosely correlated
+2.58%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+2.58%
RCKT - DNLI
53%
Loosely correlated
-2.45%
RGNX - DNLI
52%
Loosely correlated
-1.71%
BEAM - DNLI
52%
Loosely correlated
+4.51%
NTLA - DNLI
50%
Loosely correlated
+4.55%
CRSP - DNLI
50%
Loosely correlated
+5.13%
More